Key statistics
On Thursday, Candel Therapeutics Inc (CADL:NMQ) closed at 4.14, 437.01% above the 52 week low of 0.77 set on Dec 05, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.02 |
---|---|
High | 4.30 |
Low | 3.97 |
Bid | 4.15 |
Offer | 4.18 |
Previous close | 3.98 |
Average volume | 417.95k |
---|---|
Shares outstanding | 32.08m |
Free float | 21.94m |
P/E (TTM) | -- |
Market cap | 127.70m USD |
EPS (TTM) | -1.74 USD |
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
- Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
- Candel Therapeutics to Present at Jefferies London Healthcare Conference 2024
- Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma
- Candel Therapeutics Showcases Innovative Cancer Therapy Candidates at 16th Annual International Oncolytic Virotherapy Conference (IOVC)
- Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting
- Candel Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
- Candel Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
- Candel Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
- Candel Therapeutics to Join Russell 3000® Index
- FDA Grants Orphan Drug Designation for CAN-3110 for the Treatment of Recurrent High-Grade Glioma
More ▼